SWOT Analysis for Titan Biotech Ltd.

Add SWOT widget to your site/app

Benjamin Graham Value Screen
Strong Performer, Getting Expensive (DVM)
Companies with 10% increase in share price over three months, with rising net profit growth
Strong Momentum: Price above short, medium and long term moving averages
Consistent Highest Return Stocks over Five Years
Relative Outperformance versus Industry over 1 Month
Relative Outperformance versus Industry over 1 Year
Stocks whose current price is 20% higher than week low, and more than previous close
PEG lower than Industry PEG
Stocks gaining versus previous close, open price and RSI
High Momentum Scores (Technical Scores greater than 50)
Relative Outperformance versus Industry over 1 Week
Relative Outperformance versus Industry over 1 Month
Overbought by Money Flow Index (MFI)
Growth in Net Profit with increasing Profit Margin (QoQ)
Companies with Low Debt
Book Value per share Improving for last 2 years
Companies with Zero Promoter Pledge
Stock gained more than 20% in one month
Negative to Positive growth in Sales and Profit with Strong Price momentum
High Volume, High Gain
Biggest Price Gainers from Open
Top Gainers
Volume Shockers
Stocks Outperforming their Industry Price Change in the Quarter

Benjamin Graham Value Screen

Strong Performer, Getting Expensive (DVM)

Companies with 10% increase in share price over three months, with rising net profit growth

Strong Momentum: Price above short, medium and long term moving averages

Consistent Highest Return Stocks over Five Years

Relative Outperformance versus Industry over 1 Month

Relative Outperformance versus Industry over 1 Year

Stocks whose current price is 20% higher than week low, and more than previous close

PEG lower than Industry PEG

Stocks gaining versus previous close, open price and RSI

High Momentum Scores (Technical Scores greater than 50)

Relative Outperformance versus Industry over 1 Week

Relative Outperformance versus Industry over 1 Month

Overbought by Money Flow Index (MFI)

Growth in Net Profit with increasing Profit Margin (QoQ)

Companies with Low Debt

Book Value per share Improving for last 2 years

Companies with Zero Promoter Pledge

Stock gained more than 20% in one month

Negative to Positive growth in Sales and Profit with Strong Price momentum

High Volume, High Gain

Biggest Price Gainers from Open

Top Gainers

Volume Shockers

Stocks Outperforming their Industry Price Change in the Quarter

Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Inefficient use of capital to generate profits - RoCE declining in the last 2 years
Inefficient use of shareholder funds - ROE declining in the last 2 years
Inefficient use of assets to generate profits - ROA declining in the last 2 years
Poor cash generated from core business - Declining Cash Flow from Operations for last 2 years
Degrowth in Revenue and Profit
Declining profitability: Falling ROCE
Sell Zone: Stocks in the sell zone based on days traded at current PE and P/BV

Stocks with Expensive Valuations according to the Trendlyne Valuation Score

Inefficient use of capital to generate profits - RoCE declining in the last 2 years

Inefficient use of shareholder funds - ROE declining in the last 2 years

Inefficient use of assets to generate profits - ROA declining in the last 2 years

Poor cash generated from core business - Declining Cash Flow from Operations for last 2 years

Degrowth in Revenue and Profit

Declining profitability: Falling ROCE

Sell Zone: Stocks in the sell zone based on days traded at current PE and P/BV

FII / FPI or Institutions increasing their shareholding
Weekly Momentum Gainers

FII / FPI or Institutions increasing their shareholding

Weekly Momentum Gainers

Average Bullish Trend - Stocks with Medium Trendlyne Momentum Score versus Benchmarks

Average Bullish Trend - Stocks with Medium Trendlyne Momentum Score versus Benchmarks

Titan Biotech Ltd. SWOT Analysis: Strengths, Weakness, Opportunity, and Threats

Titan Biotech Ltd. has 25 Strengths, 8 Weaknesses, 2 Opportunities and 0 Threats. The SWOT product gives you a quick x-ray of a stock's outlook and potential

Benjamin Graham Value Screen

Strong Performer, Getting Expensive (DVM)

Companies with 10% increase in share price over three months, with rising net profit growth

Strong Momentum: Price above short, medium and long term moving averages

Consistent Highest Return Stocks over Five Years

Relative Outperformance versus Industry over 1 Month

Relative Outperformance versus Industry over 1 Year

Stocks whose current price is 20% higher than week low, and more than previous close

PEG lower than Industry PEG

Stocks gaining versus previous close, open price and RSI

High Momentum Scores (Technical Scores greater than 50)

Relative Outperformance versus Industry over 1 Week

Relative Outperformance versus Industry over 1 Month

Overbought by Money Flow Index (MFI)

Growth in Net Profit with increasing Profit Margin (QoQ)

Companies with Low Debt

Book Value per share Improving for last 2 years

Companies with Zero Promoter Pledge

Stock gained more than 20% in one month

Negative to Positive growth in Sales and Profit with Strong Price momentum

High Volume, High Gain

Biggest Price Gainers from Open

Top Gainers

Volume Shockers

Stocks Outperforming their Industry Price Change in the Quarter

Stocks with Expensive Valuations according to the Trendlyne Valuation Score

Inefficient use of capital to generate profits - RoCE declining in the last 2 years

Inefficient use of shareholder funds - ROE declining in the last 2 years

Inefficient use of assets to generate profits - ROA declining in the last 2 years

Poor cash generated from core business - Declining Cash Flow from Operations for last 2 years

Degrowth in Revenue and Profit

Declining profitability: Falling ROCE

Sell Zone: Stocks in the sell zone based on days traded at current PE and P/BV

FII / FPI or Institutions increasing their shareholding

Weekly Momentum Gainers

Average Bullish Trend - Stocks with Medium Trendlyne Momentum Score versus Benchmarks